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There has been an unprecedented interest in the modulatory effects of intranasal oxytocin on human social
cognition and behaviour, however as yet no study has actually demonstrated that this modality of
administration increases concentrations of the peptide in the brain as well as blood in humans. Here using
combined blood and cerebrospinal fluid (CSF) sampling in subjects receiving either 24 IU of oxytocin (n5
11) or placebo (n5 4) we have shown that oxytocin levels significantly increased in both plasma and CSF.
However, whereas oxytocin plasma concentrations peaked at 15 min after intranasal administration and
decreased after 75 min, CSF concentrations took up to 75 min to reach a significant level. Moreover, there
was no correlation (r 5 ,0.10) between oxytocin plasma and CSF concentrations. Together, these data
provide crucial insights into the plasma and CSF kinetics of intranasally administered oxytocin.
T
he neuropeptide oxytocin (OXT) has recently emerged as playing a key role in human social cognition and
behaviour. Current perspectives on the neural circuits underlying OXT effects on human social cognition
and behaviour suggest a modulation of regions involved in social-emotional processing, with altered amyg-
dala activation in response to facial expressions of emotion being one of the most consistent findings1–3.
Increasingly, clinical studies have generated unprecedented interest in the therapeutic targets and potential
benefits of intranasal OXT application for neuropsychiatric disorders characterised by social dysfunction, such
as social anxiety, autism, and schizophrenia4.
Despite extensive research and very promising results, however, little is known about the pharmacokinetic
characteristics of intranasal OXT application. Investigations into the potential effects of OXT in humans were
initially hampered by the knowledge derived from animal-based work that approximately 0.01% of the peptide
crossed the blood-brain barrier (BBB) following intravenous injection5 and that peripherally administered pep-
tides have a very brief half-life6. Consequently, the most convincing animal studies of functional effects of OXT
have therefore used intracerebroventricular or intracerebral administration routes. However, recently, intranasal
application of OXT has been shown to increase the OXT content in microdialysates sampled within the dorsal
hippocampus and the amygdala in rats and mice, which was preceded by a rather rapid rise in plasma concen-
tration7. Moreover, it has been shown that insulin, melanocyte-stimulating hormone, and vasopressin can all
cross the BBB and increase cerebrospinal fluid (CSF) as well as blood concentrations within 15–30 min after
intranasal administration8. Furthermore, intranasal delivery has been used to transport a wide range of ther-
apeutics into the CNS, for example neurotrophines (e.g., insulin-like growth factor [IGF]-1), neuropeptides (e.g.,
hypocretin-1 and exendin), cytokines (e.g., erythropoietin), and carbamazepine9,10. The direct-to-the-brain
delivery of therapeutics via the nasal route may engage extraneuronal/perineuronal routes along trigeminal or
olfactory nerve pathways; other mechanisms of entry such as bulk flow, transport via lymphatic channels,
intraneuronal transport, and active or passive transport from vasculature are also possible4. Moreover, intrana-
sally delivered OXT may cause some of its central effects by stimulating the endogenous OXT system, which
secretes OXT into the peripheral circulation but also distributes it within the brain – via targeted synaptic/
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Preliminary results have suggested that OXT nasal spray may
increase peptide levels in both peripheral blood and saliva.
Elevated OXT plasma concentrations peaking at 10–40 min after
intranasal administration of OXT (30 IU) have been documented
in threemale volunteers11. Two other studies have shown increases in
OXT plasma concentrations 30–40 min after intranasal administra-
tion of 24 IU12,13. OXT saliva concentrations have also been reported
to increase dramatically and for up to 7 h after intranasal admin-
istration of either 16 or 24 IU14, but may not be a valid biomarker
when measured by immunoassay15.
In the present study, we have examined whether OXT concentra-
tions increase in the CSF as well as blood following intranasal admin-
istration. We have also investigated the correlation between altered
plasma and CSF concentrations.
Results
As expected, there was an increase in plasma concentrations follow-
ing OXT intranasal treatment (one-way ANOVA F 5 14.408, p ,
0.001; df 5 6; Figure 1A). Post-hoc Bonferroni tests showed that
OXT plasma levels were elevated at 15, 30, 45, and 60 min (all p ,
0.001) compared to baseline. Concentrations at the 75 and 90 min
time points were lower than those at 15, 30 and 45 min (all p, 0.05)
and those at 90 minwere lower than at 60 min (p, 0.05). A one-way
ANOVA showed no changes across time points in the PLC treated
group (F 5 0.782; p 5 0.595; df 5 6). Plasma concentrations did not
differ between the two groups at baseline (OXT, mean 6 SD, 8.0 6
4.3 pg/ml; PLC,mean6 SD, 5.96 2.8 pg/ml, p. 0.05 t-test) or at 90
minutes (OXT, 12.3 6 6.0 pg/ml; PLC, 5.0 6 1.6 pg/ml; p . 0.05)
after drug application.
There was no correlation between CSF and plasma concentrations
of OXT across the coincident sampling time points (Spearman cor-
relation r 5 0.10, p 5 0.714). In general, mean CSF levels of OXT in
the PLC group were much higher than those in plasma (mean 6 SD
CSF, 19.1 6 2.4 pg/ml; plasma, 6.2 6 2.4 pg/ml; t 5 26.097, p 5
0.009).
Mean CSF concentrations of OXT significantly differed between
the sampling time points and treatment groups (F 5 6.434, p 5
0.009). Specifically, post-hoc Bonferroni tests showed that CSF con-
centrations were elevated following intranasal OXT administration
after 75 min compared with the PLC group (p 5 0.024) or with the
group of OXT-treated subjects sampled at 45 min (p 5 0.011)
(Figure 1B). Notably, CSF levels of OXT in subjects sampled at 45
and 60 minutes post nasal spray application did not differ from the
PLC group (p . 0.05). Moreover, there was no difference between
CSF levels of OXT in subjects sampled at 60 and 75 minutes post
OXT treatment (p . 0.05).
Discussion
The present study is the first to show that intranasal administration
of OXT at the 24 IU dose which is given in the majority of beha-
vioural and neuroimaging studies leads to increased OXT concen-
trations in the human CSF. However, at this dose, increases are
relatively modest and not significant until 75 min after intranasal
administration. On the other hand OXT increases in plasma are
much greater and more rapid but have returned to baseline by
75 min after intranasal treatment. Thus, overall there is no signifi-
cant correlation between CSF and plasma concentrations of the pep-
tide. We also found that basal concentrations of OXT are higher in
CSF than those in plasma.
Our finding of elevated OXT concentrations in the CSF after
intranasal OXT application is in line with the recent demonstration
of elevated OXT content in the extracellular fluid within the septum
and dorsal hippocampus of rats andmicemonitored by intracerebral
microdialysis, which peaked between 30 and 60 min after intranasal
application of OXT and was accompanied by a sharp but independ-
ent rise in plasma OXT7. It is also in line with numerous reports of
modulatory effects of OXT on human social cognition and beha-
viour, particularly in the domain of social-emotional processing1–3.
While our results are in general agreement with the only previous
report on effects of intranasal administration of other neuropeptides
on CSF and plasma concentrations in humans8, the time-courses and
magnitude of changes in the two studies are different. Specifically,
Born and colleagues8 reported up to 4-fold significant increases in
CSF concentrations following administration of arginine vasopressin
(AVP) after only 10 min at a dose of 80 IU, althoughwith a dose of 40
IU the increase took up to 60 min to occur. Comparing the two sets
of results one possible interpretation is that high doses of intranasal
peptide administration result in both a more rapid and greater con-
centration change in the CSF. Perhaps this is a little surprising given
that circulation of CSF in the brain should be relatively constant;
however, when an intranasally given peptide penetrates into the CSF
at higher concentrations, it may create a greater concentration gra-
dient which could likely accelerate the occurrence of increases in the
remotest part of the system, the lumbar spine. Since we found amore
than 60% increase in peptide concentrations after 75 min it seems
possible that at later sampling time points concentrationsmight have
increased even further. Interestingly, a recent study involving mon-
Figure 1 | Plasma and CSF kinetics of oxytocin (OXT) administered
intranasally at a dose of 24 IU. (A) Shown are OXT plasma concentrations
(mean 6 SD) immediately before (baseline, 0 min) and after intranasal
OXT or placebo (PLC) treatment. OXT plasma concentrations reached a
plateau after 15 min and decreased after 60 min. Given for each time point
in this period is the percentage increase (corrected for the lowest OXT
concentration at 0 min) over PLC mean (0–90 min). (B) Shown are
oxytocin (OXT) cerebrospinal fluid (CSF) concentrations following
intranasal oxytocin (OXT) or placebo (PLC) treatment. CSF levels took up
to 75 min to reach a significantly increased level in the OXT group. Given
is the percentage increase (corrected for the lowest OXT concentration at
45 min) over PLC mean (45–75 min). Abbreviation: cOXT, oxytocin
concentration.
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keys reported that following intranasal/mouth administration of
OXT at a dose of 25 IU CSF concentrations increased from around
20 to 50 pg/ml after 35 min; however, CSF sampling was done higher
up in the CSF system by cervical puncture, whichmight contribute to
the observed discrepancy between studies16.
The mechanism by which intranasal administration of peptides
leads to increased CSF and blood levels of the peptide remains
unclear. Intraneuronal and/or extraneuronal pathways could be
involved. For instance, the peptide could be taken up by olfactory
neurons and conveyed within these neurons via axonal transport9.
However, this would take several hours. Thus, extraneuronal path-
ways involving trigeminal10 and/or subarachnoid17 routes appear
more likely. Other mechanisms of entry such as bulk flow, transport
via lymphatic channels, and active or passive transport from vascu-
lature are also possible4. On the other hand, increased central levels of
OXT after intranasal administration could also occur indirectly
through afferent feedback signals from the periphery, which may
stimulate endogenous release within the brain but also secretion into
peripheral circulation, thereby further elevating blood OXT levels.
Thus the present findings do not necessarily represent evidence of a
direct nose-to-brain penetration of OXT. Increased concentrations
in bloodmay result from absorption by the heavily vascularized nasal
mucosa, which drains through both fenestrated epithelium and via
several facial veins into the peripheral circulation4. Indeed, a study in
rodents found that constriction of these vessels by phenylephrine
significantly reduced blood concentrations of neuropeptides given
intranasally without reducing CSF concentrations18.
The lack of correspondence between CSF and plasma OXT con-
centrations in our study supports previous observations in mon-
keys19, sheep5, and humans20 and suggests some degree of caution
in assuming that blood OXT concentrations are always an accurate
reflection of those occurring in the brain20. The higher basal concen-
trations of OXT we found in CSF compared to plasma is likely to be
due to its diffusion from the extracellular fluid, where it is highly
concentrated7, and its 30–40-fold increased half-life in CSF19. Other
animal-based studies have also reported higher and more prolonged
increased concentrations of OXT in CSF compared to blood5. From
these observations it is clear that OXT concentrations are constantly
high in the CSF and that a paracrine mode of action is quite likely.
This may help to explain why a simple intranasal application that
elevates brain CSF concentrations can promote complex behavioural
changes by targeting receptors simultaneously across widely distrib-
uted brain regions. A limitation in our current study however was
that the lack of correspondence between CSF and plasma OXT con-
centration was only explored 45, 60 and 75 min after intranasal
administration. It is conceivable that CSF OXT levels could have
risen significantly and declined again before 45 min in some subjects
in the current study, although the previous study showing rapid
appearance of AVP concentration at a 80IU dose also showed that
elevated concentrations were maintained for the remaining 70 min
of the sampling period8. A similar long lasting effect on brain OXY
concentrations was also shown in rats7 and both studies generally
support evidence for a prolonged half-life of OXT and AVP in CSF19.
Nevertheless, future studies are needed to evaluate the correspond-
ence of plasma and CSF concentrations of OXT following intranasal
application outside the limited time window of the current study.
Themajority of previous studies using single-dose intranasal OXT
administration have used the same 24 IU dose that we chose for the
current study1–4. These studies generally wait at least 45 min after
administration before conducting behavioural and neuroimaging
experiments which can last an hour or more. Given the time-course
of the plasma and CSF changes we have observed it is clear that by
75 min after intranasal administration (i.e. in the middle of many
tasks) OXT concentrations are only just increasing in CSF (at least at
the lumbar spine level) and that by this time changes may have
disappeared in the blood. Thus, there is some support for considering
delaying starting tasks following this dose of OXT a little longer than
45 min. Alternatively, given the possibility of reduced time-course
effects of increased doses of intranasal OXT experiments could start
earlier than 45 min if higher doses are used. However, this needs
further experimental confirmation.
There are several limitations to the present study. The first and
major limitation concerns the small sample size with eleven indivi-
duals in the OXT group and four in the PLC group. However, pre-
vious studies8 included only four to seven volunteers, and it is
difficult to obtain ethical approval for large-scale studies. We also
observed very consistent OXT concentrations across subjects.
Nevertheless, studies involving low numbers of subjects do require
some caution until further replication will increase confidence.
Secondly, the study only measured CSF concentrations at one time
point in each subject (45, 60 or 75 minutes) and we could only use
OXT CSF concentrations in the PLC group to provide a baseline. We
cannot rule out that the subjects showing increased CSF levels at
75 min might by chance have been those with better uptake into
the cerebroventricular system and might therefore also have shown
elevated levels at the 45 or 60 min time points. Measuring the CSF
concentration at one time point in each subject was imposed because
our subjects were undergoing specific diagnostic sampling. However,
OXT concentrations in PLC treated subjects and in the OXT treated
subjects at the 45 and 60 min time points were very similar. Further,
the final CSF sample was taken 75 minutes after intranasal OXT
administration and was the only one to show significantly increased
OXT concentrations. It is possible that at later time points OXT
concentrations would have increased even further, perhaps to the
3–4 fold level observed in other studies8,16. Future studies are needed
to evaluate the precise duration of elevated OXT concentrations in
CSF after intranasal OXT treatment, although since the total volume
of CSF is renewed every 4–5 h in humans21 it is unlikely that effects
could outlast this period of time. Finally, we do not know precisely
how long it actually takes for intranasal oxytocin to reach the lumbar
spine as opposed to the brain ventricles although it is unlikely that
this delay is more than 5–10 min or so given a 1–5 mm/s transport
speed21,22.
In conclusion, to our knowledge this is the first study that provides
evidence that intranasally administered OXT elevates OXT concen-
trations in human plasma and CSF and that kinetics of changes in
these compartments are different.
Methods
Participants. Adult male volunteers (OXT group: n 5 11, age range, 24–64 years,
mean age6 SD, 46.76 12.0 years; placebo (PLC) group: n5 4, age range 19–63 years,
mean age, 42.5 6 18.9 years) participated in this study after providing written
informed consent in accordance with the Declaration of Helsinki. The study protocol
had been approved by both the institutional ethics review board (IRB) of the Medical
Faculty of the University of Bonn and the German Federal Institute of Drugs and
Medical Devices (BfArM). At the time this study took place, all subjects were
inpatients of the Department of Neurology of the University of Bonn and underwent
routine lumbar puncture (LP) for diagnostic purposes due to polyneuropathy (n 5
11), peripheral facial nerve paresis (n 5 3), or to exclude a subarachnoid hemorrhage
(n 5 1). Two patients were subsequently excluded from our study, one due to
diagnosis of multiple sclerosis (encephalomyelitis disseminata) and another one due
to problems with CSF sampling. All participants included in our study were free of
current or past endocrine or psychiatric disorders, as assessed by medical history and
a Structured Clinical Interview for DSM-IV axis I (SCID-I)23 and axis II disorders
(SCID-II)24. Volunteers were naive to prescription-strength psychoactive medication
and had not taken any over-the-counter psychoactive medication in the past 4 weeks.
Subjects were asked to avoid the intake of alcohol for at least 24 h prior to this study.
Neuropsychological screening. All participants completed a comprehensive
neuropsychological test battery (Table 1). Specifically, neuropsychological testing
before study enrollment included the LPS 4 (‘Leistungspruefsystem Subtest 4’)25 to
assess nonverbal reasoning IQ, the MWT-B (‘Mehrfach-Wortschatz-Intelligenztest
Teil B’)26 to assess verbal IQ based on lexical decisions, and the trail-making test
(TMT)27 part A and B to assess visual attention and task-switching performance.
Furthermore, depressive symptoms were assessed by the self-report BDI (Beck’s
Depression Inventory, Version II)28.
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Study design. In this double-blind, randomized, placebo-controlled, between-subject
study we measured OXT concentrations in plasma and CSF after intranasal OXT or
PLC administration. Subjects were randomly assigned to receive either intranasal
OXT (24 IU; Syntocinon spray manufactured by Novartis, Rotkreuz, Switzerland; 3
puffs per nostril, each with 4 IU OXT) or PLC (sodium chloride solution) treatment.
To control dosing and absorption all subjects administered the nasal spray in a head
upright position, closed one nostril with one finger while administering the spray to
the other nostril and sniffing during administration. The bottle was inserted 1 cm
into the nostril with an administration angle of 45 degrees into the nose. According to
the guidelines for intranasal OXT administration by Guastella et al. subjects self-
administered the nasal spray under supervision of the experimenter and after
receiving verbal instructions and observing a demonstration by them29. CSF was
taken by lumbar puncture (LP) in a sitting position at 45 min (OXT, n 5 4; PLC n 5
1), 60 min (OXT, n 5 4; PLC, n 5 2) or 75 min (OXT, n 5 3; PLC, n 5 1) after
intranasal administration. To control for circadian variability, all LPs were carried out
at the same time of day (01:00–03:45 p.m.). After taking CSF for routine diagnostic
purposes (leukocytes and erythrocyte cell count, glucose, lactate, and total protein
content), a further volume of 10–12 ml was collected in polypropylene tubes for OXT
assay. Plasma levels of OXT were analysed based on blood samples drawn via an
intravenous catheter at 7 consecutive time points over a time window of 95 min: the
first one 5 min before drug application (baseline) and then again at 15, 30, 45, 60, 75
and 90 min after intranasal treatment. Blood was collected in 2.7 ml lithium-heparin
cell preparation tubes. To inhibit activity of proteinases, aprotinin (Sigma-Aldrich, St.
Louis, MO) was immediately added to blood and CSF samples (aprotinin 0.1 mg/
1 ml) and centrifugedwithin one hour after sampling for 15 min at 1600 g and 4uC to
remove cells. The supernatant was aliquoted into Eppendorf tubes and frozen at
280uC until assays were performed. CSF samples containing more than 500
erythrocytes per ml (prior to centrifugation) were excluded from the analysis.
Endocrine measures. CSF and plasma OXT was extracted and quantified by a highly
sensitive and specific radioimmunoassay (RIAgnosis, Munich, Germany)7,20.
Statistics. Statistical analyses were performed using IBM SPSS statistics 20 software
(IBM, Armonk, NY). After testing for normal distribution (Shapiro-Wilks), one-way
parametric ANOVA tests were used to analyse differences in CSF and blood
concentrations of OXT at different time points following the intranasal treatments.
When significance (p , 0.05) was reached, post-hoc Bonferroni tests were used to
compare concentrations at individual time points. Correlations between plasma and
CSF concentrations across all time points were analysed using a Spearman rank test.
Differences in baselineOXT concentrations in blood andCSF in PLC-treated subjects
were analysed using paired t-tests.
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